EXBLIFEP - cefepime and enmetazobactam injection

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Review first - source-specific qualification

Use the fixed-combination table only with its source qualifications

The retrieved dated label has different infusion times by renal category, ambiguous printed MDRD units and an ended marketing entry.

Before applying: Confirm the current exact product and units; retain this as a qualified snapshot, not a cefepime-only substitute.

Evidence for this qualification

Selected-source qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

EXBLIFEP - cefepime and enmetazobactam injection

Product / population: EXBLIFEP fixed-combination intravenous cefepime/enmetazobactam for its adult indication; not single-agent cefepime. Dated label/currency review remains open.
Renal measure: MDRD eGFR; table prints mL/min without indexing denominator

Selected sections only; not a complete prescribing monograph or independent clinician approval.

Exact DailyMed HTML identity and named sections read. Raw SPL XML, original document hash and complete revision history were not obtained. Availability is not established by label retrieval.

Renal dosing, restrictions and evidence limits

The dated label names MDRD eGFR but prints mL/min without an indexing denominator. Its adult table gives combined doses: 60-129, 2.5 g every 8 hours over 2 hours; >=130, the same dose/interval over 4 hours; 30-59, 1.25 g every 8 hours; 15-29, 1.25 g every 12 hours; below 15 or intermittent HD, first-day 1.25 g loading dose then 0.625 g every 24 hours. All reduced regimens infuse over 2 hours; give after HD.

For changing renal function, check serum creatinine/eGFR at least daily. Neurotoxicity can occur despite appropriate adjustment. The retrieved 2024 label has an ended marketing entry: confirm the current product and renal-measure convention, and do not substitute a cefepime-only table.

Source revision: 2/2024 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2da031b1-07ff-48f3-88d2-7e86ba93048a

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

EXBLIFEP - cefepime and enmetazobactam injection

Authored v5.8; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

A regimen is reported in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

EXBLIFEP - cefepime and enmetazobactam injection

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Dialysis evidence: A regimen is reported in selected content

EXBLIFEP fixed-combination intravenous cefepime/enmetazobactam for its adult indication; not single-agent cefepime. Dated label/currency review remains open.

Renal method: MDRD eGFR; table prints mL/min without indexing denominator
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Use the fixed-combination table only with its source qualifications

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Read 1 difference / caution notes Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

combination metric and currency hold

Use the fixed-combination table only with its source qualifications

The retrieved dated label has different infusion times by renal category, ambiguous printed MDRD units and an ended marketing entry.

How to use this: Confirm the current exact product and units; retain this as a qualified snapshot, not a cefepime-only substitute.

EXBLIFEP - cefepime and enmetazobactam injection Cefepime

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

Official source

EXBLIFEP - cefepime and enmetazobactam injection

EXBLIFEP fixed-combination intravenous cefepime/enmetazobactam for its adult indication; not single-agent cefepime. Dated label/currency review remains open.

Method: MDRD eGFR; table prints mL/min without indexing denominator

Renal dosing, restrictions and evidence limits Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope EXBLIFEP - cefepime and enmetazobactam injection

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2da031b1-07ff-48f3-88d2-7e86ba93048a

Exact product and population

EXBLIFEP fixed-combination intravenous cefepime/enmetazobactam for its adult indication; not single-agent cefepime. Dated label/currency review remains open.

RDM58-SCOPE-cefepime-enmetazobactam-exblifep · Source section: Selected source product scopeRenal section finder

Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official Compare this source

EXBLIFEP - cefepime and enmetazobactam injection

Open original reference

Open / share this exact local source

DailyMed / Allecra Therapeutics SAS · EXBLIFEP fixed-combination intravenous cefepime/enmetazobactam for its adult indication; not single-agent cefepime. Dated label/currency review remains open.

Renal method: MDRD eGFR; table prints mL/min without indexing denominator
Source date: 2/2024
Retrieved: 2026-09-10

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Dialysis evidence: A regimen is reported in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

RDM58-official-cefepime-enmetazobactam-exblifep-8be928f85a-C1 · Source locator: Sections 2.2 (Table 1), 5.2; document-end metadata and marketing information

Source-specific limits

Selected sections only; not a complete prescribing monograph or independent clinician approval.

Exact DailyMed HTML identity and named sections read. Raw SPL XML, original document hash and complete revision history were not obtained. Availability is not established by label retrieval.

Source identity and provenance

Source family: product_label
Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2da031b1-07ff-48f3-88d2-7e86ba93048a
Retrieved: 2026-09-10
Exact label title: EXBLIFEP - cefepime and enmetazobactam injection
DailyMed Set ID: 2da031b1-07ff-48f3-88d2-7e86ba93048a
Labeler: Allecra Therapeutics SAS
Label revision: 2/2024
SPL version: 3
FDA application: NDA216165
Renal-function method: MDRD eGFR; table prints mL/min without indexing denominator
Source date/version: 2/2024
Hash meaning: SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256: a1c19e2e99e80e2e73cd34d9f13f39245bd2f4dac0ca6cc7fc71ca1c1661dabd

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2da031b1-07ff-48f3-88d2-7e86ba93048a
Source retrieval: 2026-09-10. This is not the source publication or label revision date.
Original source type: source summary
Local text SHA-256: b80ecd1ce047b70a7c557884d8166f6d62ba7f690cbb952c5a1fb58e46f0b727
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report